Monoolein cubic nanoparticles as novel carriers for docetaxel

Dawoud, Mohamed; Abourehab, Mohammed A. S.; Abdou, Randa

doi:10.1016/j.jddst.2020.101501

Cited by 28 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metallic nanoparticles have shown their outstanding role in biomedical applications [13,[33][34][35]. Currently, these materials can be manufactured and functionalized with groups that facilitate their conjugation with antibodies, drugs, and ligands-these modifications and functionalization open new avenues of potential applications in magnetic separation, biotechnology, and drug delivery.…”

Section: Metallic Nanoparticlesmentioning

confidence: 99%

“…Moreover, metal nanoparticles can be manufactured while modulating their size and morphology as well as functionalization with other ligands, which widen their applications and increase their efficiencies [32,40]. Additionally, biodegradable biomaterials that Metallic nanoparticles have shown their outstanding role in biomedical applications [13,[33][34][35]. Currently, these materials can be manufactured and functionalized with groups that facilitate their conjugation with antibodies, drugs, and ligands-these modifications and functionalization open new avenues of potential applications in magnetic separation, biotechnology, and drug delivery.…”

Section: Metallic Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

et al. 2022

View full text Add to dashboard Cite

Neurological disorders (NDs) are recognized as one of the major health concerns globally. According to the World Health Organization (WHO), neurological disorders are one of the main causes of mortality worldwide. Neurological disorders include Alzheimer’s disease, Parkinson′s disease, Huntington′s disease, Amyotrophic lateral sclerosis, Frontotemporal dementia, Prion disease, Brain tumor, Spinal cord injury, and Stroke. These diseases are considered incurable diseases because no specific therapies are available to cross the blood-brain barrier (BBB) and reach the brain in a significant amount for the pharmacological effect in the brain. There is a need for the development of strategies that can improve the efficacy of drugs and circumvent BBB. One of the promising approaches is the use of different types of nano-scale materials. These nano-based drugs have the ability to increase the therapeutic effect, reduce toxicity, exhibit good stability, targeted delivery, and drug loading capacity. Different types and shapes of nanomaterials have been widely used for the treatment of neurological disorders, including quantum dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, liposomes, and micelles. These nanoparticles have unique characteristics, including sensitivity, selectivity, and the ability to cross the BBB when used in nano-sized particles, and are widely used for imaging studies and treatment of NDs. In this review, we briefly summarized the recent literature on the use of various nanomaterials and their mechanism of action for the treatment of various types of neurological disorders.

show abstract

Section: Metallic Nanoparticlesmentioning

confidence: 99%

Section: Metallic Nanoparticlesmentioning

confidence: 99%

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Docetaxel (DTX) is an active derivative of paclitaxel. DTX can inhibit the depolymerization of microtubules, ultimately resulting in the loss of function of forming microtubule bundles and thereby inhibiting the mitosis of cancer cells (Rafiei and Haddadi, 2019 ; Dawoud et al, 2020 ; Ertugen et al, 2020 ; Li et al, 2021 ). Therefore, DTX was used to incorporate into the copolymer mixed micelle for tumor chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Rational Design of Hyaluronic Acid-Based Copolymer-Mixed Micelle in Combination PD-L1 Immune Checkpoint Blockade for Enhanced Chemo-Immunotherapy of Melanoma

Zhou

Dong

Song

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The application of combinational therapy breaks the limitation of monotherapy and achieves better clinical benefit for tumor therapy. Herein, a hyaluronic acid/Pluronic F68-based copolymer-mixed micelle was constructed for targeted delivery of chemotherapeutical agent docetaxel (PHDM) in combination with programmed cell death ligand-1(PD-L1) antibody. When PHDM+anti-PDL1 was injected into the blood system, PHDM could accumulate into tumor sites and target tumor cells via CD44-mediated endocytosis and possess tumor chemotherapy. While anti-PDL1 could target PD-L1 protein expressed on surface of tumor cells to the immune checkpoint blockade characteristic for tumor immunotherapy. This strategy could not only directly kill tumor cells but also improve CD8+ T cell level and facilitate effector cytokines release. In conclusion, the rational-designed PHDM+anti-PDL1 therapy strategy creates a new way for tumor immune-chemotherapy.

show abstract

“…Docetaxel is a chemotherapeutic drug that belongs to the family of taxanes [1]. It is obtained through a semi-synthetic route from the natural compound 10deacetylbaccharine III, which is extracted from Yew trees (Taxus baccata) [2].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, commercial formulations such as Taxotere R and Duopafei R are composed of surfactants, which limit their clinical application due to side effects, such as musculoskeletal toxicity, neurotoxicity, and neutropenia. Besides that, the drug's lack of selectivity increases systemic toxicity [1,13].…”

Section: Introductionmentioning

confidence: 99%

Reversed‐phase high‐performance liquid chromatography: A fast and efficient analytical method to quantify docetaxel‐loaded pegylated liposomes in release study

Fernandes

Eloy

Victorelli

et al. 2021

J of Separation Science

View full text Add to dashboard Cite

Docetaxel is an anticancer that belongs to the family of taxanes and acts in the inhibition of cell proliferation through the polymerization of microtubules. The aim of this study was the development and validation of a fast method by reversed-phase high-performance liquid chromatography for quantitative analysis of docetaxel encapsulated in pegylated liposomes. The analytical method was validated for the following recognized specifications: system suitability, precision (repeatability and intermediate precision), linearity, accuracy, selectivity, detection and quantification limits, and robustness. The reversed phase-highperformance liquid chromatography analyses were performed at a temperature of 45 • C (isocratic mode). The mobile phase was composed of acetonitrile and water (65:35, v/v) and the flow rate was fixed at 0.8 mL/min. The running time and wavelength were 8 min and 230 nm, respectively. The method was found to be linear, precise, selective, precise, robust, accurate, in the range of 1-75 μg/mL (R 2 = 0.9999) and the values of detection and quantification limits were 2.35 and 7.84 μg/mL, respectively. The release rates of docetaxel in pegylated liposomes were lower compared to docetaxel in solution. The reversed phase highperformance liquid chromatography method developed proved to be adequate and can be effectively used to determine the in vitro release profile of docetaxel transported by pegylated liposomes.

show abstract

Monoolein cubic nanoparticles as novel carriers for docetaxel

Cited by 28 publications

References 36 publications

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

Rational Design of Hyaluronic Acid-Based Copolymer-Mixed Micelle in Combination PD-L1 Immune Checkpoint Blockade for Enhanced Chemo-Immunotherapy of Melanoma

Reversed‐phase high‐performance liquid chromatography: A fast and efficient analytical method to quantify docetaxel‐loaded pegylated liposomes in release study

Contact Info

Product

Resources

About